PH12021550096A1 - Compositions of fcrn antibodies and methods of use thereof - Google Patents

Compositions of fcrn antibodies and methods of use thereof

Info

Publication number
PH12021550096A1
PH12021550096A1 PH1/2021/550096A PH12021550096A PH12021550096A1 PH 12021550096 A1 PH12021550096 A1 PH 12021550096A1 PH 12021550096 A PH12021550096 A PH 12021550096A PH 12021550096 A1 PH12021550096 A1 PH 12021550096A1
Authority
PH
Philippines
Prior art keywords
compositions
methods
fcrn antibodies
fcrn
antibodies
Prior art date
Application number
PH1/2021/550096A
Other languages
English (en)
Inventor
Siddhesh Patil
Narinder Singh
Louis Gregory St
Eva Williams
Zhongli Zhang
Original Assignee
Momenta Pharmaceuticals Inc
Louis Gregory St
Zhongli Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc, Louis Gregory St, Zhongli Zhang filed Critical Momenta Pharmaceuticals Inc
Publication of PH12021550096A1 publication Critical patent/PH12021550096A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PH1/2021/550096A 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof PH12021550096A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701467P 2018-07-20 2018-07-20
PCT/US2019/042597 WO2020023310A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PH12021550096A1 true PH12021550096A1 (en) 2022-03-28

Family

ID=69180697

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/550096A PH12021550096A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Country Status (16)

Country Link
US (1) US20210299255A1 (enExample)
EP (1) EP3826641A4 (enExample)
JP (1) JP7457704B2 (enExample)
KR (1) KR20210105872A (enExample)
CN (1) CN113301903A (enExample)
AU (1) AU2019312139B2 (enExample)
BR (1) BR112021001017A2 (enExample)
CA (1) CA3106669A1 (enExample)
CR (1) CR20210088A (enExample)
EA (1) EA202190335A1 (enExample)
IL (1) IL280280B2 (enExample)
JO (2) JOP20210015A1 (enExample)
MX (1) MX2021000790A (enExample)
PH (1) PH12021550096A1 (enExample)
SG (1) SG11202100420UA (enExample)
WO (1) WO2020023310A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
CN116782939A (zh) * 2020-11-06 2023-09-19 动量制药公司 FcRn抗体及其使用方法
CA3200972A1 (en) * 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
MX2023012032A (es) * 2021-04-12 2023-12-08 Momenta Pharmaceuticals Inc Composiciones y métodos para tratar la miastenia gravis pediátrica.
EP4658368A1 (en) 2023-02-04 2025-12-10 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
CN116539488B (zh) * 2023-05-11 2023-11-24 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备
TW202527982A (zh) * 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
EP2225269A2 (en) * 2007-11-09 2010-09-08 Anaphore, Inc. Fusion proteins of mannose binding lectins for treatment of disease
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
JP2018527903A (ja) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos

Also Published As

Publication number Publication date
JOP20210014A1 (ar) 2021-01-19
KR20210105872A (ko) 2021-08-27
CA3106669A1 (en) 2020-01-30
AU2019312139B2 (en) 2025-02-06
WO2020023310A1 (en) 2020-01-30
JP7457704B2 (ja) 2024-03-28
US20210299255A1 (en) 2021-09-30
MX2021000790A (es) 2021-07-21
SG11202100420UA (en) 2021-02-25
EP3826641A1 (en) 2021-06-02
BR112021001017A2 (pt) 2021-05-04
EP3826641A4 (en) 2022-04-20
JOP20210015A1 (ar) 2021-01-19
AU2019312139A1 (en) 2021-02-04
JP2021531346A (ja) 2021-11-18
IL280280B2 (en) 2024-11-01
IL280280A (en) 2021-03-25
IL280280B1 (en) 2024-07-01
CN113301903A (zh) 2021-08-24
EA202190335A1 (ru) 2021-06-11
CR20210088A (es) 2021-09-02

Similar Documents

Publication Publication Date Title
JOP20210015A1 (ar) تركيبات مضادات fcrn وطرق استخدامها
MX2025000260A (es) Proteina de union al antigeno anti-steap1
PH12020551716A1 (en) Anti-ror antibody constructs
WO2017220989A8 (en) ANTI-PD-L1 AND CYTOKINES IL-2
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
IL281778A (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2018015274A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2023014154A (es) Anticuerpos anti-ccr8.
MX2022006784A (es) Formulaciones de anticuerpos anti-pd-l1.
MX2019010999A (es) Formulaciones que comprenden proteinas de union a pd-1 y metodos para preparar las mismas.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
PH12021551470A1 (en) Antibody that binds to vegf and il-1beta and methods of use
PH12023550112A1 (en) Anti-notch2 antibodies and methods of use
EP4257195A3 (en) Anti-cfae antibodies and methods of use
MX2020012016A (es) Sistemas y metodos para cuantificar y modificar la viscosidad de proteinas.
MX2023015206A (es) Formulaciones de anticuerpos anti-tgf-beta y su uso.